STAA (STAAR Surgical) Q2 2026: 111% Revenue Surge Fueled by China EVO+ Adoption and Operational Leverage
STAAR Surgical’s second quarter 2026 marked a pronounced inflection with revenue more than doubling year-over-year, driven predominantly by rapid EVO+ lens adoption in China and sustained global market share gains. Operational improvements, including a successful ERP system rollout, underpinned margin expansion and a return to profitability. The company’s strategic shift toward innovation acceleration and platform diversification signals a long-term growth trajectory beyond its core EVO ICL franchise.
Summary
- Market Share Expansion: Strong lens-based refractive surgery adoption in China and the Americas is reshaping competitive dynamics.
- Operational Discipline: ERP implementation and supply chain investments are enhancing scalability and margin expansion.
- Innovation Focus: Transitioning from a single product to a diversified platform with next-generation R&D underway.
Business Overview
STAAR Surgical (STAA) is a global leader in phakic intraocular lenses (IOLs), specializing in the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction. The company generates revenue primarily through sales of these lenses, with major markets including China, the Americas, Asia-Pacific (APAC) excluding China, and Europe, Middle East, and Africa (EMEA). Its business model centers on proprietary lens technology, surgeon training programs, and expanding market penetration in refractive surgery — a procedure correcting myopia and astigmatism without removing corneal tissue.
Performance Analysis
In Q2 2026, STAAR achieved net sales of $93.5 million, reflecting an extraordinary 111% increase year-over-year. This surge was largely propelled by China, which accounted for over half of total revenue with $52.3 million in sales, up more than 100% and growing 10% sequentially. Excluding China, net sales rose a more modest 6%, underscoring the regional variability in growth. The Americas and EMEA (excluding the Middle East) each posted double-digit growth, while APAC ex-China saw a 7% increase. Gross margin improved to 74.5%, driven by operational efficiencies including the elimination of ramp-up costs in Switzerland and lower inventory provisions, partially offset by tariff-related expense pressures on U.S.-made products sold in China.
Profitability returned robustly with net income of $8.1 million compared to a prior-year loss, supported by disciplined expense management and improved gross profit. Adjusted EBITDA was $20 million, a stark reversal from the previous year's loss. The company’s cash position strengthened to $181.5 million, reflecting strong free cash flow generation despite ongoing investments in ERP and supply chain enhancements.
- China Growth Engine: EVO+ lens adoption exceeded expectations, comprising nearly one-third of China’s unit volume by quarter-end and commanding a premium price that sustained ASP (average selling price) expansion.
- Operational Efficiency: ERP system implementation, while resource-intensive, stabilized without materially impacting revenue, enabling improved business visibility and scalability.
- Regional Dynamics: While China led growth, Japan and Korea contributed solid unit volume gains despite currency headwinds, and the U.S. market showed sustained momentum with consecutive $6 million quarters.
Overall, STAAR demonstrated a successful execution of its growth, profit, and innovation priorities, positioning the company for sustained expansion amid evolving refractive surgery market dynamics.
Executive Commentary
"We grew revenue, expanded gross margins, generated net income, and built cash. We have much to be proud of, growing EVO Plus adoption in China, back-to-back record quarters in the U.S., a successful ERP implementation, and early progress in organizing our product pipeline."
Warren Foust, President and Chief Executive Officer
"Our second quarter results reflect tangible progress across key areas, with revenue, gross margin and net income all growing both year-over-year and sequentially. We successfully navigated the complexities of our ERP cutover while maintaining our focus on efficiency and growth."
Deborah Andrews, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. China Market Leadership and EVO+ Adoption
China remains STAAR's largest and fastest-growing market, accounting for over 50% of revenue. The EVO+ lens launch has outpaced supply expectations, driving sequential growth and a premium ASP. The company is capitalizing on shifting refractive surgery seasonality and increasing market share from laser-based procedures, supported by a favorable product mix including higher-priced toric lenses. Management emphasizes no excess inventory at distributors, underscoring demand-driven growth.
2. Expanding Global Footprint with Focused Regional Investment
Beyond China, STAAR is selectively investing in markets with clear return potential, such as Japan, Korea, the Americas, and EMEA (excluding the Middle East). Japan’s direct-to-consumer awareness campaigns have bolstered unit volume despite currency challenges. In the U.S., the company targets surgeon training and practice economics to convert laser-based procedure volume to EVO ICL, evidenced by consecutive $6 million quarters. EMEA growth is strong outside the Middle East, reflecting solid commercial execution.
3. Operational Excellence and Scalability via ERP and Supply Chain
The successful ERP system implementation marks a foundational upgrade, improving operational visibility and enabling future AI-driven efficiencies. Despite initial consulting and amortization costs, the system has not materially disrupted revenue. Supply chain investments aim to resolve production constraints, particularly for EVO+ lenses, with expectations to meet demand fully by late Q3. This operational discipline supports margin expansion and improved incremental revenue-to-EBITDA conversion.
4. Innovation Acceleration and Platform Diversification
STAAR is transitioning from a single-product company to a broader platform, leveraging its proprietary Collamer material. The company is preparing for first-in-human studies of next-generation products and is actively recruiting a Chief Technology Officer to lead innovation. This strategic pivot aims to capture a larger share of the refractive surgery market by expanding beyond EVO ICL, including potential opportunities in presbyopia correction and extended depth of focus lenses.
5. Financial Discipline and Long-Term Value Creation
Management emphasizes disciplined expense management, maintaining operating expenses within target ranges despite strategic investments. The company’s strong balance sheet, absence of debt, and growing cash reserves provide flexibility to invest selectively. The focus remains on profitable growth, operating leverage, and sustainable free cash flow generation as key pillars for long-term shareholder value.
Key Considerations
STAAR’s Q2 performance reflects a pivotal moment in its growth trajectory amid evolving refractive surgery market dynamics and internal transformation.
- Seasonality Shift in China: The first two quarters now represent peak revenue periods due to factors like Chinese New Year and military recruitment screenings, with Q3 expected to moderate but still deliver year-over-year growth.
- Supply Constraints and Inventory Management: EVO+ demand outstripped supply earlier in the year but is approaching balance as production scales; tariff impacts persist until full Swiss manufacturing for China shipments is achieved.
- Market Share Gains vs. Market Growth: Despite a modest or uneven overall refractive surgery market, STAAR’s lens-based approach is gaining share from laser procedures, signaling a structural industry shift.
- U.S. Market Development: Adoption remains early but promising, with surgeon confidence and economic models key to expanding EVO ICL’s footprint amid a declining laser market.
- Innovation Pipeline Uncertainty: While next-generation products are advancing, timelines and impact remain to be fully disclosed, with CTO recruitment underscoring a strategic inflection.
Risks
STAAR faces risks including ongoing geopolitical tensions impacting the Middle East and China markets, tariff costs on U.S.-made products, supply chain constraints, and competitive pressures from emerging domestic lens manufacturers. Additionally, macroeconomic factors and currency fluctuations, especially in APAC, could affect growth. The success of innovation efforts depends on regulatory approvals and market adoption, introducing execution risk.
Forward Outlook
For Q3 2026, STAAR anticipates year-over-year growth despite expected seasonal moderation in China, using an adjusted comparable base excluding a one-time $25.9 million order from 2024. Management expects to continue growing revenue in Q4, albeit from a softer seasonal base.
- Q3 revenue expected to grow moderately over adjusted 2025 base of $68.8 million.
- Gross margin pressure from tariffs expected to ease as Swiss manufacturing for China shipments reaches 100% by year-end.
Management highlighted continued investments in supply chain scaling, surgeon training, and innovation pipeline development as key drivers for sustained growth and margin expansion in the coming periods.
Takeaways
STAAR’s Q2 2026 results underscore a successful execution of its strategic priorities, positioning the company for durable growth in a shifting refractive surgery landscape.
- Robust China Growth and Market Share Gains: The EVO+ launch is a clear catalyst, driving premium pricing and volume growth, validating the company’s differentiated lens-based approach.
- Operational and Financial Discipline: ERP implementation and supply chain investments are foundational for scalable growth, with profitability and cash flow returning strongly.
- Strategic Innovation Pivot: Transitioning to a diversified product platform anchored by proprietary Collamer technology sets the stage for long-term value creation beyond the core EVO ICL franchise.
Conclusion
STAAR Surgical’s second quarter performance reflects a significant inflection point, combining market share acceleration, operational improvements, and strategic innovation initiatives. While near-term seasonality and supply challenges require management attention, the company’s clear priorities and robust execution provide a compelling outlook for sustained growth and profitability in the evolving refractive surgery market.
Industry Read-Through
STAAR’s results highlight a broader industry shift favoring lens-based refractive surgery over traditional laser procedures, driven by patient and surgeon preferences for reversible, cornea-preserving solutions. The strong EVO+ adoption in China, despite a challenging macro environment, signals growing acceptance of premium lens technologies. Competitors and investors should monitor the pace of innovation pipeline development and operational scalability, as these factors will increasingly differentiate market leaders in ophthalmology. Additionally, the evolving seasonality in China and tariff-driven supply chain adjustments underscore the importance of localized manufacturing and market-specific strategies in global medtech sectors.